Skip to content

Wave Life Sciences WVE Debt-to-equity

Debt-to-equity at other companies

Eli Lilly logo
Eli LillyLLY
1.4×-1.1×
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
0.1×0.0×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
1.4×+1.1×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
0.7×+0.5×
ALN
Alnylam PharmaceuticalsALNY
0.2×-0.4×
Beam Therapeutics logo
Beam TherapeuticsBEAM
0.2×+0.1×

Other financials

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Cash & equivalents$544.6M+124%
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation

See full
Market cap$1.14B+13.0%
Enterprise value$615.92M-22.3%
P/S15.1×-12.2×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-53.7%
Current ratio11.3×+8.3×

Where this comes from

Calculated from Wave Life Sciences’s reported figures.

Based on the most recent quarter.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Wave Life Sciences's debt-to-equity?
Wave Life Sciences (WVE) reported debt-to-equity of 0× in Q1 2026.
How has Wave Life Sciences's debt-to-equity changed year-over-year?
Wave Life Sciences's debt-to-equity decreased by 77.7% year-over-year, from 0.1× to 0×.
What is the long-term trend for Wave Life Sciences's debt-to-equity?
Over 4 years (2020 to 2025), Wave Life Sciences's debt-to-equity has grown at a -44.2% compound annual growth rate (CAGR), from 0.4× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.